# A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

> **NCT02723773** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 7539 (actual)

## Conditions studied

- Herpes Zoster
- Herpes Zoster Vaccine

## Interventions

- **BIOLOGICAL:** Herpes Zoster Vaccine GSK1437173A

## Key facts

- **NCT ID:** NCT02723773
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-16
- **Primary completion:** 2023-06-28
- **Final completion:** 2024-01-30
- **Target enrollment:** 7539 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723773, "A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02723773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*